Description:

The Summit is the leading industry-dedicated meeting focused on advancing personalized cancer immunotherapy through neoantigen targeting.

Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into space means that tumor-specific antigen targeting is set to explode.

At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:
• Reducing the discordance between various neoantigen prediction methods
• Maximizing the immune response to neoantigens
• Shortening the needle-to-needle time of personalized cancer immunotherapy
• Navigating the evolving regulatory landscape to faster approval

Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody, the European Medicines Agency and many more to spur on more efficacious personalized cancer vaccines and cell therapies.

FOCUS DAY-Tue 23rd Apr

Join this workshop to learn and discuss:
• Key advances in in silico MHC ligand prediction through mass spectrometry data
• Minimizing time and cost of the neoantigen selection, prediction and validation process
• Challenges and improvements in predicting the T-cell reponse

In this workshop, attendees will learn and discuss:
• Current regulatory requirements in the clinical development and manufacturing of neoantigen based cancer immunotherapy
• Requirements to demonstrate convincing efficacy in neoantigen targeting
• What are the key considerations to take into account when working with regulatory body?